Literature DB >> 29285050

Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.

Ting Liu1, Feng Guo1, Xiaomin Zhu1, Xiangge He1, Lin Xie1.   

Abstract

The US Food and Drug Administration approved thalidomide and its analogues for the treatment of erythema nodosum leprosum, in spite of the notoriety of reports of severe birth defects in the middle of the last century. As immunomodulatory drugs, thalidomide and its analogues have been used to effectively treat various diseases. In the present review, preclinical data about the effects of thalidomide and its analogues on the immune system are integrated, including the effects of cytokines on transdifferentiation, the anti-inflammatory effect, immune cell function regulation and angiogenesis. The present review also investigates the latest developments of thalidomide as a therapeutic option for the treatment of idiopathic pulmonary fibrosis, skin fibrosis, and ophthalmopathies.

Entities:  

Keywords:  idiopathic pulmonary fibrosis; immunomodulatory drugs; opthalmopathies; skin fibrosis; thalidomide

Year:  2017        PMID： 29285050      PMCID： PMC5740745          DOI： 10.3892/etm.2017.5209

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN： 1792-0981            Impact factor:   2.447


  77 in total

1.  Immune stimulation in scleroderma patients treated with thalidomide.

Authors:  S J Oliver; A Moreira; G Kaplan
Journal:  Clin Immunol       Date:  2000-11       Impact factor: 3.969

Review 2.  The evolution of thalidomide and its IMiD derivatives as anticancer agents.

Authors:  J Blake Bartlett; Keith Dredge; Angus G Dalgleish
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

3.  Isotrifoliol inhibits pro-inflammatory mediators by suppression of TLR/NF-κB and TLR/MAPK signaling in LPS-induced RAW264.7 cells.

Authors:  Hua Li; Jeong-Hyun Yoon; Hyo-Jun Won; Hyeon-Seon Ji; Heong Joo Yuk; Ki Hun Park; Ho-Yong Park; Tae-Sook Jeong
Journal:  Int Immunopharmacol       Date:  2017-02-10       Impact factor: 4.932

4.  Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway.

Authors:  Peng Lv; He-Sheng Luo; Xiao-Ping Zhou; Yan-Jv Xiao; Shelley Chireyath Paul; Xin-Min Si; Yan-Hong Zhou
Journal:  Arch Med Res       Date:  2007-01       Impact factor: 2.235

Review 5.  Protein kinase C-theta (PKC theta): a key enzyme in T cell life and death.

Authors:  Amnon Altman; Martin Villalba
Journal:  J Biochem       Date:  2002-12       Impact factor: 3.387

6.  Thalidomide in the treatment of immune reconstitution inflammatory syndrome in HIV patients with neurological tuberculosis.

Authors:  Camille Fourcade; Jean-Marc Mauboussin; Catherine Lechiche; Jean-Philippe Lavigne; Albert Sotto
Journal:  AIDS Patient Care STDS       Date:  2014-10-06       Impact factor: 5.078

Review 7.  Properties of thalidomide and its analogues: implications for anticancer therapy.

Authors:  Steven K Teo
Journal:  AAPS J       Date:  2005-03-22       Impact factor: 4.009

8.  Immune modulatory effect of thalidomide on T cells.

Authors:  B S Kim; J Y Kim; J G Lee; Y Cho; K H Huh; M S Kim; Y S Kim
Journal:  Transplant Proc       Date:  2015-04       Impact factor: 1.066

9.  lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.

Authors:  Lei Wu; Mary Adams; Troy Carter; Roger Chen; George Muller; David Stirling; Peter Schafer; J Blake Bartlett
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

10.  IgG4-related skin disease successfully treated by thalidomide: a report of 2 cases with emphasis on pathological aspects.

Authors:  Saskia Ingen-Housz-Oro; Nicolas Ortonne; Muriel Elhai; Yannick Allanore; Pierre Aucouturier; Olivier Chosidow
Journal:  JAMA Dermatol       Date:  2013-06       Impact factor: 10.282
View more
  9 in total

1.  Thalidomide remodels developing heart in chick embryo: discovery of a thalidomide mediated hematoma in heart muscle.

Authors:  Pavitra Kumar; Harish A Kumar; Lakshmikirupa Sundaresan; Anuran Ghosh; Priyadarshan Kathirvel; Apurva Thilak; Yash T Katakia; Kavitha Sankaranarayanan; Suvro Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-07       Impact factor: 3.000

Review 2.  Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases.

Authors:  Abdur Rauf; Himani Badoni; Tareq Abu-Izneid; Ahmed Olatunde; Md Mominur Rahman; Sakshi Painuli; Prabhakar Semwal; Polrat Wilairatana; Mohammad S Mubarak
Journal:  Molecules       Date:  2022-05-17       Impact factor: 4.927

Review 3.  Molecular Mechanisms and Current Treatment Options for Cancer Cachexia.

Authors:  Syed Sayeed Ahmad; Khurshid Ahmad; Sibhghatulla Shaikh; Hye Jin You; Eun-Young Lee; Shahid Ali; Eun Ju Lee; Inho Choi
Journal:  Cancers (Basel)       Date:  2022-04-23       Impact factor: 6.575

Review 4.  Overcoming cancer therapeutic bottleneck by drug repurposing.

Authors:  Zhe Zhang; Li Zhou; Na Xie; Edouard C Nice; Tao Zhang; Yongping Cui; Canhua Huang
Journal:  Signal Transduct Target Ther       Date:  2020-07-02

Review 5.  Dually Efficacious Medicine Against Fibrosis and Cancer.

Authors:  Daohong Chen
Journal:  Med Sci (Basel)       Date:  2019-03-04

6.  Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.

Authors:  Kidae Kim; Dong Ho Lee; Sungryul Park; Seung-Hyun Jo; Bonsu Ku; Sung Goo Park; Byoung Chul Park; Yeong Uk Jeon; Sunjoo Ahn; Chung Hyo Kang; Daehee Hwang; Sehyun Chae; Jae Du Ha; Sunhong Kim; Jong Yeon Hwang; Jeong-Hoon Kim
Journal:  Sci Rep       Date:  2019-12-23       Impact factor: 4.379

Review 7.  A review of COVID-19: Treatment strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease.

Authors:  Muhammad Farhat Ullah; Yasir Ali; Muhammad Ramzan Khan; Inam Ullah Khan; Bing Yan; M Ijaz Khan; M Y Malik
Journal:  Saudi J Biol Sci       Date:  2021-10-13       Impact factor: 4.219

Review 8.  Diagnostic and Treatment Strategies for COVID-19.

Authors:  Humzah Jamshaid; Fatima Zahid; Intisar Ud Din; Alam Zeb; Han Gon Choi; Gul Majid Khan; Fakhar Ud Din
Journal:  AAPS PharmSciTech       Date:  2020-08-03       Impact factor: 3.246

Review 9.  Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments.

Authors:  Yoo Jin Jung; David Tweedie; Michael T Scerba; Nigel H Greig
Journal:  Front Cell Dev Biol       Date:  2019-12-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.